We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
+56.71%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$180M
AUM Growth
+$12.1M
(+7.2%)
Cap. Flow
+$13.4M
Cap. Flow
% of AUM
7.43%
Top 10 Holdings %
Top 10 Hldgs %
65.55%
Holding
34
New
12
Increased
4
Reduced
5
Closed
12
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$13.8M |
| 2 |
CG Oncology
CGON
|
+$13.1M |
| 3 |
VRNA
Verona Pharma
VRNA
|
+$12.7M |
| 4 |
RAPT
RAPT Therapeutics
RAPT
|
+$7.3M |
| 5 |
Kura Oncology
KURA
|
+$7.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$13.3M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
+$11.6M |
| 3 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.1M |
| 4 |
APLS
Apellis Pharmaceuticals
APLS
|
+$8.98M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
+$8.66M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
BPMC
1
DELISTED
Blueprint Medicines
BPMC
| $15.3M | 8.49% |
+160,950
| New | +$13.8M |
|
|
SLNO
2
DELISTED
Soleno Therapeutics
SLNO
| $14.4M | 8.01% |
336,486
+26,536
| +9% | +$1.2M |
|
|
3
CG Oncology
CGON
$6.34B
| $14.1M | 7.82% |
+320,378
| New | +$13.1M |
|
4
Xenon Pharmaceuticals
XENE
$6.6B
| $13.3M | 7.4% |
309,369
+67,408
| +28% | +$3.1M |
|
|
VRNA
5
DELISTED
Verona Pharma
VRNA
| $11.9M | 6.59% |
+736,738
| New | +$12.7M |
|
|
MRUS
6
DELISTED
Merus
MRUS
| $11.5M | 6.41% |
255,928
-18,995
| -7% | -$770K |
|
7
Praxis Precision Medicines
PRAX
$8.77B
| $9.73M | 5.41% |
159,486
+89,062
| +126% | +$4M |
|
|
DFTX
8
Definium Therapeutics
DFTX
$5.88B
| $9.41M | 5.23% |
+1,001,452
| New | +$5.71M |
|
|
AVDL
9
DELISTED
Avadel Pharmaceuticals
AVDL
| $9.24M | 5.14% |
547,036
+200,000
| +58% | +$2.98M |
|
10
Geron
GERN
$924M
| $9.11M | 5.06% |
2,760,497
-211,142
| -7% | -$473K |
|
11
Jasper Therapeutics
JSPR
$29.4M
| $8.51M | 4.73% |
289,943
-75,983
| -21% | -$1.35M |
|
|
12
Kura Oncology
KURA
$964M
| $7.79M | 4.33% |
+365,044
| New | +$7.1M |
|
13
Insmed
INSM
$23.5B
| $6.78M | 3.77% |
+250,000
| New | +$7M |
|
14
Dianthus Therapeutics
DNTH
$5.77B
| $6.51M | 3.62% |
+216,968
| New | +$4.72M |
|
15
Olema Pharmaceuticals
OLMA
$1B
| $6.33M | 3.52% |
559,035
-100,000
| -15% | -$1.29M |
|
|
LYRA
16
DELISTED
LYRA THERAPEUTICS INC
LYRA
| $6.24M | 3.47% |
+20,075
| New | +$5.35M |
|
|
LBPH
17
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $5.84M | 3.25% |
+270,559
| New | +$5.9M |
|
|
RAPT
18
DELISTED
RAPT Therapeutics
RAPT
| $3.77M | 2.1% |
+52,500
| New | +$7.3M |
|
|
MRSN
19
DELISTED
Mersana Therapeutics
MRSN
| $3.59M | 2% |
+32,057
| New | +$3.19M |
|
|
MRNS
20
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $3.57M | 1.98% |
+394,773
| New | +$3.84M |
|
21
ProMIS Neurosciences
PMN
$136M
| $2.02M | 1.13% |
42,383
-284
| -0.7% | -$14.1K |
|
22
Context Therapeutics
CNTX
$55.1M
| $1M | 0.56% |
725,951
| – | – |
|
23
Amylyx Pharmaceuticals
AMLX
$1.97B
| – | – |
-275,773
| Closed | -$4.06M |
|
|
APLS
24
DELISTED
Apellis Pharmaceuticals
APLS
| – | – |
-150,000
| Closed | -$8.98M |
|
|
25
argenx
ARGX
$53.8B
| – | – |
-35,000
| Closed | -$13.3M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q1 2024 Portfolio in Review
As of Q1 2024, Ally Bridge Group held 34 positions worth $180M, up 7.2% from $168M the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Ally Bridge Group deployed $13.4M of net new capital in Q1 2024, opening 12 new positions and adding to 4 existing holdings. Its largest new stake was Blueprint Medicines: 160,950 shares worth $15.3M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier.
On the sell side, the largest reduction was Jasper Therapeutics, an estimated $1.35M trimmed.
- Ally Bridge Group's largest Q1 2024 buy was Blueprint Medicines: 160,950 shares worth $15.3M.
- Ally Bridge Group added most to Praxis Precision Medicines in Q1 2024, an estimated $4M increase.
- Ally Bridge Group's biggest Q1 2024 reduction was Jasper Therapeutics, cutting an estimated $1.35M.
- Ally Bridge Group fully exited argenx in Q1 2024, selling an estimated $13.3M.
- Ally Bridge Group's ten largest holdings make up 66% of its $180M portfolio in Q1 2024.
- Ally Bridge Group opened 12 new positions and closed 12 in Q1 2024.
- Ally Bridge Group's portfolio value rose 7.2% quarter-over-quarter to $180M.
Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.